Related Experiment Video

Updated: Mar 1, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

27.0K

Dopaminergic Imaging and Prodromal Parkinson Disease: A Key Biomarker Arrives

Ronald B Postuma1

  • 1Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada.

JAMA Neurology
|June 9, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.7K

Related Experiment Videos

Last Updated: Mar 1, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

27.0K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.7K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K

Articles linked to this work by shared authors, journal, and citation graph.

The Relationship Between Resting State Quantitative EEG and Daytime Sleepiness Complaints in Parkinson's Disease.

Journal of sleep research·2026

Association Between Plasma Phosphorylated Tau-217 and Cognition in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Brain-first and body-first subtypes of Lewy body disease.

Nature reviews. Neurology·2026

Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's disease.

NPJ Parkinson's disease·2026

Smartphone-derived digital motor measures to monitor progression in idiopathic REM sleep behavior disorder.

NPJ Parkinson's disease·2026

Selective molecular and network architecture features underlie brain cortical atrophy in dementia with Lewy bodies.

Journal of biomedical science·2026

Intravenous Immunoglobulin Add-On in Newly Diagnosed Idiopathic Inflammatory Myopathies: A Randomized Clinical Trial.

JAMA neurology·2026

Clinical Characteristics, Neuroimaging Findings, and Mortality in Korsakoff Syndrome.

JAMA neurology·2026

Common MC1R Variants and Parkinson Disease Progression.

JAMA neurology·2026

Smoking, Exhaled Carbon Monoxide, and Risk of Parkinson Disease.

JAMA neurology·2026

Tirofiban for Branch Atheromatous Disease-Related Stroke: The STRATEGY Randomized Clinical Trial.

JAMA neurology·2026

Lifelong De Novo Aneurysm Risk After Aneurysmal Subarachnoid Hemorrhage in Young Survivors.

JAMA neurology·2026

Analgesic Efficacy of Different Doses of Esketamine as an Adjuvant to Ropivacaine for Thoracoscopy-Guided Thoracic Paravertebral Block After Thoracoscopic Radical Resection for Lung Cancer: A Prospective Randomized Controlled Trial.

Drug design, development and therapy·2026

A quantitative framework for the rational design of long-acting epidural therapeutics.

International journal of pharmaceutics·2026

Elucidating drug-carrier interactions and release from PCL and PLA microspheres prepared by PES membrane emulsification: a strategy integrating molecular docking.

International journal of pharmaceutics·2026

Cargo-aware design of dissolving microneedles: an FEA-guided rational framework reveals distinct delivery mechanisms for small and large molecules.

International journal of pharmaceutics·2026

From discovery to clinic: Medicinal chemistry strategies for PROTAC linker optimization.

European journal of medicinal chemistry·2026

From Reflection to Implementation: Tailored Clinical Development of a Pembrolizumab Biosimilar Candidate.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us